Bio-Rad Laboratories Inc (BIO)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $9.85B
Last updated: Nov 17, 2026 at 11:05 AM ET
Bio-Rad Laboratories Inc (BIO) Stock Forecast
Analysts expect Bio-Rad Laboratories (BIO) to earn $9.61 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.57B. Of 3 analysts, 1 rates the stock Buy or Strong Buy, 1 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 3.00, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 33% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 33.3% |
| Buy | 0 | 0.0% |
| Hold | 1 | 33.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 33.3% |
- Consensus
- Hold
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 3.1% and revenue estimates rise 1.6%.
- Fiscal year ending Dec 31, 2026
- $9.61
- EPS consensus, revenue $2.57B
- Fiscal year ending Dec 31, 2027
- $9.91
- EPS consensus, revenue $2.61B
- Next report
- Feb 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $9.61 | $8.85 to $10.09 | 3 | $2.57B | $2.53B to $2.59B | 3 |
| Dec 31, 2027 | $9.91 | $8.75 to $10.60 | 3 | $2.61B | $2.53B to $2.65B | 3 |
Quarterly Estimates
The EPS consensus falls from $2.86 for the quarter ending Dec 31, 2026 to $2.83 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.86 | $2.68 to $3.07 | 4 | $695.54M | $672.98M to $725.13M | 4 |
| Mar 31, 2027 | $2.83 | $2.83 to $2.83 | 1 | $611.30M | $611.30M to $611.30M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 4 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1.4% from $9.48.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $9.61 | $9.45 | $9.45 | $9.48 | $9.48 | +1.3% |
| Fiscal year ending Dec 31, 2027 | $9.91 | $9.75 | $9.92 | $10.03 | $10.03 | -1.2% |
| Quarter ending Mar 31, 2027 | $2.83 | $2.98 | $3.10 | $2.48 | $2.48 | +14.0% |
Frequently Asked Questions About BIO
What is the BIO stock forecast?
Consensus analyst estimates put Bio-Rad Laboratories's EPS at $9.61 for the fiscal year ending Dec 31, 2026, on revenue of $2.57B. The consensus rating from 3 analysts is Hold.
How do analysts rate BIO stock?
Of 3 analysts covering Bio-Rad Laboratories, 1 rates it Strong Buy, 0 Buy, 1 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from BIO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $9.61, with estimates from $8.85 to $10.09 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $9.91, with estimates from $8.75 to $10.60 from 3 analysts.
What revenue do analysts expect from Bio-Rad Laboratories next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.57B, with estimates from $2.53B to $2.59B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $2.61B, with estimates from $2.53B to $2.65B.
How many analysts cover BIO?
3 analysts rate Bio-Rad Laboratories stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
BIO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors